Sunny big player: Giofini film, second listed;

original title: Tianqing big player: Jifeitinib tablets, the second listing, the competitive landscape intensified
1.5Gifitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor, suitable for primary treatment of patients with sensitive mutations in epidermal growth factor receptor genes in patients with local late or metastatic non-small cell lung cancer, and for the treatment of patients with pre-chemical treatment of local advanced or metastatic non-small cell lung cancer patients, has been included in the 2005 China Clinical Guidelines and recommendedThe prescription composition and process of the Giffeitinib tablets developed by Zhengda Tianqing are basically the same as those of the original research products, and the results of the bioequivalence test confirm that they are biologically equivalent to the reference preparationThe introduction of the drug could bring new hope to patients with pre-experimental late-stage or metastatic non-small cell lung cancer and their families, while high-quality and low-cost domestic drugs can also help reduce the financial burden on patients2After the first round of 4 plus 7, Qilu Pharmaceuticals (Hainan) adjusted the price of Jifeitinib tablets (size 0.25g, packaging 10 tablets/box) to 498 boxes3.4 plus 7 episodes, AstraZeneca's original Giifitini film (250mg x 10 pieces) was selected at 547 yuan, a decrease of 76%references:Pharmaceutical Melt data, Pharnex Datamonitor; Pharmaceutical meltingpublic disclosure by related companies; and so on